Foghorn Therapeutics Ownership
| FHTX Stock | USD 4.68 0.44 10.38% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 62.6 M | Current Value 62.6 M | Avarage Shares Outstanding 33.3 M | Quarterly Volatility 14.8 M |
Foghorn Stock Ownership Analysis
About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.74. Foghorn Therapeutics had not issued any dividends in recent years. Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Foghorn Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people. To learn more about Foghorn Therapeutics call Adrian Gottschalk at 617 586 3100 or check out https://foghorntx.com.Foghorn Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Foghorn Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Foghorn Therapeutics backward and forwards among themselves. Foghorn Therapeutics' institutional investor refers to the entity that pools money to purchase Foghorn Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-12-31 | 567.4 K | Alphabet Inc | 2024-12-31 | 500.9 K | Birchview Capital, Lp | 2024-12-31 | 310.9 K | Northern Trust Corp | 2024-12-31 | 253.7 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 223.8 K | Dafna Capital Management Llc | 2024-12-31 | 186.7 K | Sio Capital Management, Llc | 2024-12-31 | 121.7 K | D. E. Shaw & Co Lp | 2024-12-31 | 100.4 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 97.5 K | Flagship Ventures Management, Inc. | 2024-12-31 | 12.7 M | Fmr Inc | 2024-12-31 | 5.7 M |
Foghorn Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Foghorn Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Foghorn Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Foghorn Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Foghorn Therapeutics Outstanding Bonds
Foghorn Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Foghorn Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Foghorn bonds can be classified according to their maturity, which is the date when Foghorn Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Foghorn Therapeutics Corporate Filings
F4 | 10th of April 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 24th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 20th of March 2025 Other Reports | ViewVerify | |
| 12th of February 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.